Home  |  Contact

Cellosaurus MCF-7 RR2 (CVCL_IU97)

[Text version]
Cell line name MCF-7 RR2
Synonyms MCF-7_RR2
Accession CVCL_IU97
Resource Identification Initiative To cite this cell line use: MCF-7 RR2 (RRID:CVCL_IU97)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:9168; Sirolimus (Rapamycin).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 3942; MTOR; Simple; p.Phe2108Leu; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=27279227).
  • Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0031 (MCF-7)
Sex of cell Female
Age at sampling 69Y
Category Cancer cell line
Publications

PubMed=27279227; DOI=10.1038/nature17963
Rodrik-Outmezguine V.S., Okaniwa M., Yao Z., Novotny C.J., McWhirter C., Banaji A., Won H., Wong W., Berger M., de Stanchina E., Barratt D.G., Cosulich S., Klinowska T., Rosen N., Shokat K.M.
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.
Nature 534:272-276(2016)

Cross-references
Cell line databases/resources cancercelllines; CVCL_IU97
Encyclopedic resources Wikidata; Q54904324
Polymorphism and mutation databases Cosmic; 2553505
Entry history
Entry creation03-Mar-2017
Last entry update05-Oct-2023
Version number13